Shots:

• The P-II ELEKTRA study involves assessing of soticlestat vs PBO in pediatric patients- aged 2-17 yrs.- with highly refractory epileptic seizures associated with DS (convulsive seizures) or LGS (drop seizures)
• Results: meeting its 1EPs i.e. reduction in DS & LGS (27.8% vs 3.1% & 29.8% vs 0.0%) during the 12-wks. maintenance period & 20-wks. treatment period (titration plus maintenance) respectively. In DS cohort- reduction in convulsive seizure (33.8% vs 7.0%) during the full 20-week treatment period- following which companies are planning to initiate P-III program
• In the LGS cohort- reduction in drop seizure frequency (20.6% vs 6.0%) during the full 20-week treatment period of the study. Soticlestat is a potent- highly selective- oral- first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H)

­ Ref: PRNewswire | Image: Takeda